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OBJECTIVES: To prospectively evaluate the long-term
societal economic and humanistic benefits of acute treat-
ment of AECB with gemifloxacin compared with
clarithromycin. METHODS: Patients with AECB were
randomized to receive acute, double-blind, double-
dummy treatment with either gemifloxacin 320 mg o.d.
for 5 days or clarithromycin 500 mg b.d. for 7 days. Pa-
tients in US (n  386) and Canadian centers (n  52)
were followed for 26 weeks from treatment initiation and
the following assessments were made: AECB recurrence
requiring antibiotic treatment; respiratory tract infection-
related: health care resource utilization, time off and per-
formance at work and usual activities; and health-related
quality of life using the St George’s Respiratory Ques-
tionnaire (SGRQ). RESULTS: In full sample analysis, sig-
nificantly more patients who received gemifloxacin re-
mained recurrence free after 26 weeks (73.8% [158/214]
vs. 63.8% [143/224]; p  0.024) and were hospitalized
less (2.34% [5/214] vs. 6.25% [14/224]; p  0.059).
Cost-effectiveness analysis indicated average direct and
indirect cost savings of $329 per patient for gemifloxacin
vs. clarithromycin. Ninety-five percent confidence inter-
vals for bootstrapped incremental cost-effectiveness ra-
tios ranged from a cost saving of $14,175 to a cost of
$8,888 per recurrence-free patient considering all costs.
There was an 82.5% probability of gemifloxacin being
both cost saving and more effective than clarithromycin
from the societal perspective. A greater improvement in
total weighted SGRQ score (lower scores being better),
adjusted for baseline, was observed for gemifloxacin vs.
clarithromycin at 4, 12 and 26 weeks after initiation of
acute treatment (43.3 vs. 44.6 [p  0.38], 39.4 vs. 41.8
[p  0.20] and 37.7 vs. 41.0 [p  0.09], respectively).
There was significantly less impact on performance at
work (p  0.01) and usual activities (p  0.03) at 26
weeks, due to bronchitis, among patients who received
gemifloxacin. CONCLUSIONS: Gemifloxacin was very
cost-effective from the societal perspective and improved
long-term patient outcomes compared with clarithromy-
cin for the treatment of AECB.
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Severe and difficult to treat asthma patients represent a
small percentage of all asthmatics, yet they account for
much of the morbidity, mortality, and cost of the disease.
The factors that make this group of asthmatics difficult
to manage are poorly understood. OBJECTIVE: To es-
tablish a cohort of severe or difficult to treat asthmatics
to examine the relationships between features of asthma,
treatments and health outcomes using the Internet.
METHODS: This study, “An Observational Study of
The Epidemiology and Natural History of Asthma: Out-
comes and Treatment Regiments (TENOR),” is designed
to follow at least 5000 subjects for 3 years. Subjects 6
years or older with a diagnosis of asthma and considered
by their physician to have severe or difficult to treat
asthma are eligible for enrollment. Physicians and coordi-
nators will conduct biannual visits to collect data includ-
ing: health care utilization, days of work or school
missed, the asthma therapy assessment questionnaire
(ATAQ), asthma-related quality of life (AQLQ), medica-
tions, IgE level, and lung function. Data will be entered
onto a secure website. RESULTS: Subjects are being en-
rolled into the cohort from over 300 US pulmonologists
and allergists in managed care organizations, community
practices, and academic centers. All study sites have In-
ternet access. The TENOR website was built using Web-
CollectSM services and PhaseForward’s InFormTM ap-
plication. Built-in edit checks and an automatic electronic
audit trail ensure data accuracy and completeness. This
technology eliminates the need for paper case report
forms and improves data cleaning efficiency. CONCLU-
SIONS: TENOR provides a unique opportunity to exam-
ine factors related to poor health outcomes in this under-
studied patient population. The Internet allows real time
access to data and facilitates dissemination of data to in-
vestigators and the asthma community. TENOR may
serve as a model for future large epidemiologic or clinical
studies using web-based technology.
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OBJECTIVE: Despite increased use in the health care
sector (HCS), the contingent valuation (CV) method re-
mains controversial. The nucleus of the controversy is the
extent to which hypothetical choices in the CV method
mimic real economic choices. Correspondence between
hypothetical and real willingness to pay (WTP) has been
studied for private and environmental goods. These ex-
periments demonstrate that dichotomous choice (DC)
CV questions lead to hypothetical bias (overestimation of
real WTP). Hypothetical bias has not been assessed in the
HCS. We conducted an experiment directly comparing
responses to a DC CV question with real purchase deci-
sions using a pharmacist provided asthma management
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service as the item being valued. We examined whether
DC CV questions lead to hypothetical bias for this good,
and we tested whether “definitely sure” hypothetical yes
responses, as identified in a follow-up question, corre-
spond to real yes responses. METHODS: 172 subjects
with asthma were recruited from 10 Kentucky commu-
nity pharmacies. Subjects received either a DC CV ques-
tion or were given the opportunity to actually purchase
the service. Three different prices were used: $15, $40,
and $80. RESULTS: In the hypothetical group 38% of
subjects stated they would purchase the good at the given
price, but only 12% of subjects in the real group pur-
chased the good (p  0.000). We cannot, however, reject
the null hypothesis that “definitely sure” hypothetical yes
responses correspond to real yes responses. CONCLU-
SIONS: The DC CV method overestimates WTP in the
HCS, but it may be possible to correct for this by sorting
out “definitely sure” yes responses.
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OBJECTIVE: The primary objective was to evaluate the
relationship between willingness to pay (WTP), quality of
life (QOL), and disease severity measures in asthma pa-
tients. The hypothesis studied was that asthma patients
with more severe disease, as measured objectively via
forced expiratory volume percent predicted (FEV1%),
are willing to pay more for a hypothetical cure from
asthma than those with less severe disease. METHODS:
One-hundred asthmatic patients were recruited from
community pharmacies in Kentucky for 30 minute face-
to-face interviews. Spirometry was used to assess ob-
jective disease severity while a multiple choice question
assessed subjective disease severity. The Short Form 36
(SF-36) and Asthma Technology of Patient Experience
(Asthma TyPE) measured QOL. WTP was obtained via a
dichotomous choice contingent valuation question. RE-
SULTS: WTP was significantly related to both objective
disease severity (p  0.02) and subjectively assessed dis-
ease severity (p  0.01). For objective disease severity the
mean monthly WTP was $90 for mild asthma, $131 for
moderate asthma and $331 for severe asthma; and for
subjective disease severity the mean monthly WTP was
$48 for mild asthma, $166 for moderate asthma and
$241 for severe asthma. A majority of the QOL measures
were correlated with WTP. CONCLUSIONS: The results
suggest that the WTP for a cure from asthma is related to
both objective and subjective disease severity.
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OBJECTIVES: Cilomilast is a potent and selective phos-
phodiesterase type 4 (PDE4) inhibitor currently under
development for the treatment of chronic obstructive pul-
monary disease (COPD) and asthma. METHODS: COPD-
related health care resource utilization including physi-
cian visits, emergency room visits, hospitalizations and
medication use were prospectively collected in a 6 month
randomized, double-blind, placebo controlled, parallel
group study of patients on cilomilast, 15 mg bid (n 
431) versus patients on placebo (n  216). Methods of
analysis included descriptive statistics, Kaplan-Meier esti-
mates and Poisson regression. RESULTS: In the year
prior to the study, COPD-related health care resource
utilization was comparable between patients eventually
randomized to cilomilast and those randomized to pla-
cebo; the majority of all patients had no or one emer-
gency room visit or hospitalziation. During the entire 24-
week study period, the cumulative incidence of health
care utilization was significantly lower in the cilomilast
group than the placebo group in terms of all utilization
(11.0% vs. 21.1%, p  0.004); including physician visits
(11.9% vs. 23.1%, p  0.002), emergency room visits
(0.6% vs. 4.5%, p  0.004) and hospitalization (0.5%
vs. 3.4%, p  0.021). The relative utilization rates per
patient-month of follow-up for each of the utilization
types were lower in the cilomilast group than in the pla-
cebo group. Treatment with cilomilast resulted in reduc-
tion of all utilization by 51% (C.I.: 31%, 65%), physi-
cian visits by 41% (C.I.: 15%, 59%). ER visits and
hospitalizations were also significantly reduced. CON-
CLUSIONS: In this study, cilomilast was associated with
significantly less COPD-related health care resource utili-
zation, including hospitalizations, emergency room visits
and physician visits than placebo.
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OBJECTIVES: Asthma is a common medical condition
that is increasing in prevalence. The purpose of this study
was to examine costs associated with treating asthma pa-
tients within a managed care organization (MCO).
METHODS: Data for this study were obtained from a
managed care organization located in the Western region
of the US. Patients were eligible for inclusion if they met
one of the following criteria: a diagnosis of asthma (ICD-
9 code of 493.xx); two or more prescriptions used to
control asthma (e.g., inhaled corticosteroid, leukotriene
